Trump's Bold Tariff Plan Targets Pharma Companies, Sparking Debate Over Drug Prices and Economic Impact

President Donald Trump has taken a bold step in his second term, unveiling a sweeping executive order that could impose tariffs of up to 100 percent on patented drugs if pharmaceutical companies fail to reach agreements with his administration. The move, announced on Thursday, aims to pressure drugmakers into lowering prices for Americans, but it has already sparked debate over its potential economic and medical consequences.

The executive order outlines a tiered system of tariffs based on companies' compliance with "most favoured nation" pricing deals and their investment in U.S. manufacturing. Companies that have signed such deals and are actively building facilities in the U.S. will face zero-percent tariffs, while those without deals but investing in domestic production will see a 20 percent tariff, rising to 100 percent in four years. A senior administration official emphasized that companies still have time to negotiate, with larger firms granted 120 days and others 180 days before the tariffs escalate.

This policy comes as part of Trump's broader strategy to use economic leverage to reshape the pharmaceutical industry. The administration has already secured 17 pricing deals with major drugmakers, with 13 finalized, according to the official. However, critics argue that the threat of steep tariffs could backfire, driving up costs for patients and deterring investment in U.S. manufacturing.

The executive order frames the tariffs as a necessary measure to address "threatened impairment of the national security posed by imports of pharmaceuticals." This justification echoes Trump's long-standing rhetoric about protecting American interests through trade policies. The timing is also significant, as the order was issued on the first anniversary of Trump's "Liberation Day," when he imposed sweeping import taxes on global trading partners—a move later overturned by the Supreme Court.

Pharmaceutical industry leaders and medical groups have raised alarms about the potential fallout. Stephen J. Ubl, CEO of PhRMA, warned that tariffs could increase costs for life-saving medicines and jeopardize billions in U.S. investments. He highlighted that many imported drugs come from reliable allies like Japan and the European Union, where manufacturing ties are already strong.

Despite the controversy, Trump's administration has used the threat of tariffs to broker deals with major companies such as Pfizer, Eli Lilly, and Bristol Myers Squibb. These agreements have promised lower prices for new drugs, though the long-term effectiveness of this approach remains unclear.

Internationally, the U.S. has also negotiated trade frameworks to cap tariffs on drugs from key partners. The European Union, Japan, South Korea, and Switzerland will face a 15 percent tariff on patented pharmaceuticals, aligning with previously agreed rates. The United Kingdom, meanwhile, will see a 10 percent tariff that could drop to zero under future trade agreements—a concession the UK secured for at least three years of zero-percent tariffs on its exports to the U.S.

As the administration pushes forward, the coming months will test whether Trump's strategy of economic pressure can achieve his goal of lowering drug costs without harming innovation or access to essential medicines. For now, the pharmaceutical industry remains in a holding pattern, watching closely as negotiations unfold.